SCHEMBL4020161

SCHEMBL4020161

O=C(O)c1ccc([N+](=O)[O-])cc1CCCCN1CCC(OC(c2ccccc2)c2ccccc2)CC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 11/20 0.66
HTR2A P28223 2/20 0.47
NPC1 O15118 1/20 0.47
MLNR O43193 1/20 0.47
NR1I2 O75469 1/20 0.47
EGFR P00533 1/20 0.47
LMNA P02545 1/20 0.47
ERBB2 P04626 1/20 0.47
FYN P06241 1/20 0.47
CHRM2 P08172 1/20 0.47
CHRM4 P08173 1/20 0.47
ABCB1 P08183 1/20 0.47
ADRB1 P08588 1/20 0.47
HTR1A P08908 1/20 0.47
CHRM5 P08912 1/20 0.47
ADRA2A P08913 1/20 0.47
ADORA3 P0DMS8 1/20 0.47
CHRM1 P11229 1/20 0.47
ADRB3 P13945 1/20 0.47
DRD2 P14416 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4023934 0.85 BCHE (0.67) BCHEHTR2A
SCHEMBL4026270 0.85 BCHE (0.64) BCHEHTR2ANPC1MLNRNR1I2
SCHEMBL4023951 0.85 BCHE (0.64) BCHEHTR2ANPC1MLNRNR1I2
SCHEMBL4021697 0.84 BCHE (0.65) BCHEHTR2ANPC1MLNRNR1I2
SCHEMBL4023303 0.84 BCHE (0.65) BCHEHTR2ANPC1MLNRNR1I2
SCHEMBL14383256 0.80 BCHE (1.00) BCHEHTR2ANPC1MLNRNR1I2
SCHEMBL4022560 0.77 BCHE (0.56) BCHEHTR2ANPC1MLNRNR1I2
SCHEMBL4023903 0.77 BCHE (0.64) BCHEHTR2ANPC1MLNRNR1I2
SCHEMBL4024417 0.77 BCHE (0.64) BCHEHTR2ANPC1MLNRNR1I2
SCHEMBL9563324 0.77 BCHE (0.69) BCHEPARP14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1446400-B1 PIPERIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE CONTAINING THE SAME STC NARA CO LTD (KR) 2009-01-28 EP claimed
US-7288552-B2 Piperidine derivatives, process for preparation thereof, and pharmaceutical composition for alzheimer's disease containing the same STC NARA CO., LTD. (KR) 2007-10-30 US claimed
EP-1446400-A4 PIPERIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE CONTAINING THE SAME STC NARA CO LTD (KR) 2005-06-01 EP claimed
US-20050043316-A1 Piperidine derivatives, process for preparation thereof, and pharmaceutical composition for alzheimer's disease containing the same STC NARA CO., LTD. (KR) 2005-02-24 US claimed
EP-1446400-A1 PIPERIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE CONTAINING THE SAME STC Nara Co. Ltd. (KR) 2004-08-18 EP claimed
WO-2003033489-A1 PIPERIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE CONTAINING THE SAME STC NARA CO., LTD. (KR) 2003-04-24 WO claimed
EP-1446400-B1 PIPERIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE CONTAINING THE SAME STC NARA CO LTD (KR) 2009-01-28 EP disclosed
US-7288552-B2 Piperidine derivatives, process for preparation thereof, and pharmaceutical composition for alzheimer's disease containing the same STC NARA CO., LTD. (KR) 2007-10-30 US disclosed
EP-1446400-A4 PIPERIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE CONTAINING THE SAME STC NARA CO LTD (KR) 2005-06-01 EP disclosed
US-20050043316-A1 Piperidine derivatives, process for preparation thereof, and pharmaceutical composition for alzheimer's disease containing the same STC NARA CO., LTD. (KR) 2005-02-24 US disclosed
EP-1446400-A1 PIPERIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE CONTAINING THE SAME STC Nara Co. Ltd. (KR) 2004-08-18 EP disclosed
WO-2003033489-A1 PIPERIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE CONTAINING THE SAME STC NARA CO., LTD. (KR) 2003-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043316-A1 Piperidine derivatives, process for preparation thereof, and pharmaceutical composition for alzheimer's disease containing the same APP, ACHE, PSEN1 BCHE 7/4885HTR2A 1505/4885NPC1 945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.